Non-invasive markers of hepatic encephalopathy under chronic hepatitis C and2-oxoglutarate treatment
DOI:
https://doi.org/10.12923/Keywords:
chronic hepatitis C, encephalopathy, S-100b, 2-oxoglutarateAbstract
The level of the non-invasive markers of hepatic fibrosis and astroglia damage under chronic hepatitis C (CHC) and 2-oxoglutarate treatment was investigated. The obtained data allow for the suggestion that S-100b level in the blood serum may be used as a marker of hepatic encephalopathy under CHC, the treatment with 2-oxoglutarate can prevent serious brain damage caused by ammonia effect.
References
1. Bajaj J.S.: Minimal hepatic encephalopathy matters in daily life. World J. Gastroenterol., 14, 3609, 2008.
2. Bongiovanni M, Casana M.: Non-invasive markers of liver fibrosis in HCV mono-infected and in HIV/HCV co-infected subjects. Med. Chem., 4, 513, 2008.
3. Bradford M.M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248, 1976.
4. Butterworth R.F.: Pathophysiology of hepatic encephalopathy: A new look at ammonia. Metab. Brain Dis., 17, 221, 2002.
5. Gold E.W.: The quantitative spectrophotometric estimation of total sulfated glycosaminoglycan levels. Formation of soluble alcian blue complexes. Biochim. Biophys. Acta, 673, 408, 1981.
6. Lai J.C., Cooper A.J.: Brain alpha-ketoglutarate dehydrogenase complex: kinetic properties, regional distribution, and effects of inhibitors. J. Neurochem., 47, 1376, 1986.
7. Nikolenko V.Y., Nikolenko Y.I., Nikolenko O.Y.: Pat. 15752 Ukraine, MPK G 09 B 23/28. Chronic hepatitis C development; Doneck State Medical University, № u2006004614.
Downloads
Published
Issue
Section
License
Copyright (c) 2010 Authors

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.